Parkinson’s Disease Case Study
Advancing Parkinson’s disease research with human midbrain organoids
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons in the midbrain. Despite extensive research, translating preclinical findings into effective therapies remains challenging due to the limited predictive value of conventional models.
Challenges
Progress in Parkinson’s disease drug development is constrained by limitations in existing experimental models, which reduce their translational relevance and regulatory confidence.
Model limitations
Oversimplified systems
Late diagnosis
Translational gap
Midbrain Organoid Models as a Solution for Parkinson’s Disease
To address these challenges, Lambda Biologics has developed an integrated Parkinson’s disease modeling approach based on human midbrain organoids. This model offers clear advantages over traditional systems by better reflecting human-specific disease biology.
Human 3D midbrain organoids
Physiologically meaningful insights
Disease-specific modeling
Drug discovery support
Discuss Your Parkinson’s Disease Research
Related Solutions
Parkinson’s Disease Modeling Workflow
We develop human Parkinson’s disease organoid models using two complementary approaches:
– Genetically engineered organoids, created by editing key Parkinson’s-related genes such as LRRK2 or SNCA.
– Patient-derived organoids, generated from iPSCs to capture patient-specific disease features.
These models enable the study of dopaminergic neuron degeneration and support translational drug discovery in a human-relevant context.
Result
Upon treatment with the mitochondrial toxin CCCP, Parkinson’s disease organoids showed:
– Reduced tyrosine hydroxylase (TH) expression, indicating dopaminergic neuron loss
– Increased cleaved caspase-3 (cCasp3) expression, indicating elevated apoptosis
These results confirm the critical role of mitochondrial dysfunction in dopaminergic neuron degeneration and demonstrate the utility of our organoid platform for studying Parkinson’s disease mechanisms and evaluating therapeutic strategies.
MitoSOX (ROS indicator)
This compound selectively binds to superoxide, a major marker of oxidative stress produced in the mitochondria. After CCCP treatment, the expression of MitoSOX was increased, indicating an elevation in mitochondrial oxidative stress. This supports the notion that mitochondrial dysfunction plays a critical role in Parkinson’s disease.
JC-1 (Mitochondrial membrane potential
Discuss Your Parkinson’s Disease Research
Impact
Validated disease model
Links mitochondrial dysfunction directly to dopaminergic neuron death in human tissueDrug screening platform
Test neuroprotective compounds in disease-relevant conditionsFuture applications
Study protein aggregation, oxidative stress, early-stage disease mechanisms, and gene-environment interactionsPrecision medicine
Patient-derived organoids enable personalized treatment strategies
Your CRO Partner for Neuroscience Drug Discovery
Read Other Case Study
